Thursday, July 20, 2017 6:32:22 PM
AEPP/Oncolix summary.
AEPP and Oncolix CEO Michael Redman discusses Oncolix, the progress of its Cancer treatment drug Prolanta, as well as announcing the completion of the Share Purchase Agreement with AEPP that he intends to use to take Oncolix public from April 24, 2017.
He also states his ambition to eventually have Oncolix listed on the NASDAQ.
He mentions the experienced Oncolix team.
The biographies of Oncolix officers, Board of Directors and company advisors have been released to the public and are available on the company website.
AEPP The Oncolix Team.
Management
Board Members
Company Advisors
Oncolix has a worldwide patent portfolio that is also available to view on the Oncolix website.
Leveraging these worldwide patents, Oncolix could be in a position to realize substantial gains in revenue and market capitalization.
AEPP currently has 93,231,633 shares outstanding. That gives AEPP a market cap of only $4,303,000 @ the current PPS. More importantly is the public float is only 33,312,000.
Oncolix has completed several rounds of private offerings that are only available to accredited investors, family trusts, endowments and institutional investors. The latest round of funding was initiated in February 2017.
Accredited investors to date include the Greenville Hospital System, the Texas Emerging Technology Fund and the Ernest Mario Family Trust among others.
Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.
Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.
Participants in these private offerings are likely investing in a royalty stake of future revenue when/if Prolanta goes to market.
Accredited investment often differs from PIPE financing that can be toxic or dilutive to current shareholders.
With the latest round of private offerings currently being completed, AEPP could continue clinical trials without any need to dilute.
IMO and FWIW.
AEPP and Oncolix CEO Michael Redman discusses Oncolix, the progress of its Cancer treatment drug Prolanta, as well as announcing the completion of the Share Purchase Agreement with AEPP that he intends to use to take Oncolix public from April 24, 2017.
He also states his ambition to eventually have Oncolix listed on the NASDAQ.
He mentions the experienced Oncolix team.
The biographies of Oncolix officers, Board of Directors and company advisors have been released to the public and are available on the company website.
AEPP The Oncolix Team.
Management
Board Members
Company Advisors
Oncolix has a worldwide patent portfolio that is also available to view on the Oncolix website.
Leveraging these worldwide patents, Oncolix could be in a position to realize substantial gains in revenue and market capitalization.
AEPP currently has 93,231,633 shares outstanding. That gives AEPP a market cap of only $4,303,000 @ the current PPS. More importantly is the public float is only 33,312,000.
Oncolix has completed several rounds of private offerings that are only available to accredited investors, family trusts, endowments and institutional investors. The latest round of funding was initiated in February 2017.
Accredited investors to date include the Greenville Hospital System, the Texas Emerging Technology Fund and the Ernest Mario Family Trust among others.
Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.
Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.
Participants in these private offerings are likely investing in a royalty stake of future revenue when/if Prolanta goes to market.
Accredited investment often differs from PIPE financing that can be toxic or dilutive to current shareholders.
With the latest round of private offerings currently being completed, AEPP could continue clinical trials without any need to dilute.
IMO and FWIW.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
